T-Cell Depleted CD34+ PBSC Transplants After Chemotherapy Conditioning as Treatment for Hematologic Malignancies and as a Platform for Cellular Immunotherapies

Richard O’Reilly, M.D. discusses current allogeneic transplant approaches, different conditioning regimens and pros/cons for different strategies. 

Target Audience

Hematologists, oncologists, pathologists, radiation oncologists, physician assistants, nurses, nurse practitioners, palliative care staff, pharmacists and other allied health care team members interested in the treatment of patients with hematologic malignancies.

Learning Objectives

  • Implement current allogeneic transplant approaches.
  • Assess strategies with the different conditioning regimen.
  • Compare the pros and cons of allogeneic transplant strategies.

Sponsors 

The Continuing Medical Education Department gratefully acknowledges the following organizations for providing support of high quality unbiased continuing medical education at the Immunotherapy Symposium, at which the content for this online activity was recorded:
 
Bristol-Meyers Squibb
Genentech
Janssen Oncology
Jazz Pharmaceuticals, Inc. 

Additional information
Bibliography: 
  • Pasquini, M.C., Devine, S., Mendizabal, A., Baden, L.R., Wingard, J.R., Lazarus, H.M.,… & O’Reilly, R. J. (2012). Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. Journal of clinical oncology, 30(26), 3194.
  • Bayraktar, U. D., de Lima, M., Saliba, R. M., Maloy, M., Castro-Malaspina, H. R., Chen, J., ... & Kernan, N. A. (2013). Ex Vivo T cell–depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation, 19(6), 898-903.
  • Tamari, R., Chung, S. S., Papadopoulos, E. B., Jakubowski, A. A., Hilden, P., Devlin, S. M., ... & Maloy, M. A. (2015). CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biology of Blood and Marrow Transplantation, 21(12), 2106-2114.
Course Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.00 Florida Board of Pharmacy
Course opens: 
05/26/2020
Course expires: 
08/04/2020

Richard O’Reilly, M.D.
Claire L. Tow Chair in Pediatric Oncology Research
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Richard O’Reilly, M.D., has indicated that he is a consultant with Atara Biotherapeutics, and he will include off-label or unapproved product usage in his presentation or discussion.

This online course is a highlight from the Inaugural Miami Cancer Institute Immunotherapies Summit.

Symposium Directors
Guenther Koehne, M.D., Ph.D.
Deputy Director of Miami Cancer Institute
Chief of Blood & Marrow Transplant and Hematologic Oncology
Miami Cancer Institute 
Miami, Florida

Robert Sackstein, M.D.
Interim Chair, Department of Translational Medicine
Dean and Senior Vice President for Health Affairs, and Professor
Florida International University
Miami, Florida

Guenther Koehne, M.D., Ph.D., has indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation or discussion.

Robert Sackstein, M.D., has indicated that he is a consultant with Biotechne/R&D Systems and Mesoblast LTD, and he has licenses with Warrior Therapeutics LLC, Mesoblast Ltd., and Biotechne/R&D Systems. He also has equity with Warrior Therapeutics, LLC. He will not include off-label or unapproved product usage in his presentation or discussion.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.00 Florida Board of Pharmacy
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome		Microsoft Edge
Microsoft Edge		Safari
Safari		Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.